A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2029

Conditions

Advanced Chronic Myeloid LeukemiaPhiladelphia Chromosome-Positive Acute Myeloid Leukemia

Interventions

DRUG

Decitabine

Given by IV

DRUG

Listaftoclax

Given by PO

DRUG

Olverembatinib

Given by PO

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston